Summary: The Centers for Medicare & Medicaid Services modified its coverage policy for Anti-Inhibitor Coagulant Complex (AICC), effective May 15, 2026. Here's what billing teams need to do.
AICC is a high-cost clotting factor product used in patients with hemophilia who have developed inhibitors against standard factor VIII or IX replacement therapy. CMS AICC coverage policy modifications carry significant financial exposure — these products can run tens of thousands of dollars per infusion episode. The policy document does not list specific CPT or HCPCS codes, so your first step is confirming which codes your team currently uses to bill AICC and mapping them to the updated requirements before May 15, 2026.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Anti-Inhibitor Coagulant Complex (AICC) |
| Policy Code | N/A |
| Change Type | Modified |
| Effective Date | May 15, 2026 |
| Impact Level | High |
| Specialties Affected | Hematology, Oncology, Infusion Therapy, Home Health, Specialty Pharmacy |
| Key Action | Audit your current AICC billing guidelines and documentation protocols before May 15, 2026 |
CMS Anti-Inhibitor Coagulant Complex Coverage Criteria and Medical Necessity Requirements 2026
The CMS AICC coverage policy applies to one of the most complex patient populations in hematology billing. AICC — sold under brand names like FEIBA (Factor Eight Inhibitor Bypassing Activity) — is a bypassing agent. It treats or prevents bleeding episodes in patients with hemophilia A or B who have developed inhibitors, making standard clotting factor replacement ineffective.
Medical necessity documentation for AICC is not optional, and it's not simple. To support a claim, you need to show that the patient has a confirmed inhibitor diagnosis, that standard replacement therapy has failed or is contraindicated, and that a qualified hematologist has ordered the product. Missing any one of those elements is a straight path to claim denial.
Because the policy data provided does not include the specific modified criteria text, billing teams should pull the full policy from the CMS source directly at https://app.payerpolicy.org/p/cms/150-v1. Read the updated language against your current documentation templates and flag any gaps. If you're unsure whether your current medical necessity language still meets the updated standard, loop in your compliance officer before the effective date.
Prior authorization requirements for AICC vary by Medicare plan type. Fee-for-service Medicare typically processes AICC under Part B when administered in a clinical setting or under Part D when dispensed for home use. Medicare Advantage plans add another layer — many require prior authorization for bypassing agents, and those requirements may have changed in alignment with this CMS update. Check your payer mix now.
Reimbursement for AICC under Medicare Part B runs through the Average Sales Price (ASP) methodology. If CMS has updated the coverage policy in a way that changes eligible indications or dosing parameters, your reimbursement calculations need to reflect the new criteria. A claim for a dose that doesn't align with covered indications will deny — and with AICC pricing, that's a denial you don't want to chase on appeal.
CMS AICC Exclusions and Non-Covered Indications
The policy data provided does not include a specific exclusions list from the modified document. That said, standard CMS exclusion patterns for clotting factor products are worth reviewing against your current billing practices.
CMS does not cover AICC when used as a first-line treatment in patients without a confirmed inhibitor diagnosis. Using a bypassing agent before documenting inhibitor presence is both a medical necessity failure and a coverage policy violation. Claims submitted without a confirmed inhibitor titer and a documented treatment failure with standard factor products will not survive review.
AICC used for prophylaxis — as opposed to acute bleed treatment or surgical coverage — occupies grayer territory. Coverage for prophylactic AICC use requires strong documentation showing that on-demand treatment has failed to control bleeding frequency, and that a hematologist has reviewed and approved the prophylactic regimen. If your practice bills prophylactic AICC, this is the area where the May 2026 modification is most likely to create friction.
Because the specific exclusion language from the modified policy is not included in the data available, do not rely on this section alone to determine what CMS will and won't cover after May 15, 2026. Get the full policy text and compare it line-by-line against your current workflows.
Coverage Indications at a Glance
The policy document provided does not include a specific indication-level breakdown. The table below reflects standard CMS AICC coverage logic based on established Medicare billing guidelines for bypassing agents. Treat this as a starting framework — verify every row against the updated policy text before May 15, 2026.
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Acute bleeding episodes in hemophilia A or B with inhibitors | Covered | Confirm current HCPCS with payer | Requires confirmed inhibitor titer and hematologist order |
| Surgical prophylaxis in inhibitor patients | Covered | Confirm current HCPCS with payer | Pre-op documentation and prior authorization typically required |
| Routine prophylaxis in inhibitor patients | Coverage varies by plan | Confirm current HCPCS with payer | Strong medical necessity documentation required; MA plans may require prior auth |
| AICC in patients without confirmed inhibitors | Not Covered | N/A | Medical necessity criteria not met |
| AICC as first-line therapy before standard factor trial | Not Covered | N/A | Coverage policy requires documented treatment failure first |
Note: This table is based on standard CMS coverage logic. The specific policy data for this modification does not include a detailed indications list. Verify all rows against the updated policy before the effective date.
CMS Anti-Inhibitor Coagulant Complex Billing Guidelines and Action Items 2026
AICC billing is high-stakes. A single denied claim can mean a five- or six-figure write-off. These steps are not optional housekeeping — they're financial protection for your practice or facility.
| # | Action Item |
|---|---|
| 1 | Pull the updated policy now. Access the full modified policy at https://app.payerpolicy.org/p/cms/150-v1. Read the updated language side-by-side with your current documentation templates. Identify every place where the criteria have shifted. |
| 2 | Audit your AICC claims from the last 12 months. Before May 15, 2026, run a report on every claim you've submitted for AICC products. Check whether your documentation would meet the updated medical necessity standard. If it wouldn't, fix your templates before the effective date — not after your first denial. |
| 3 | Confirm your HCPCS codes with your MAC. The policy does not list specific billing codes. AICC products are typically billed under HCPCS J-codes, but code assignments change. Contact your Medicare Administrative Contractor to confirm which codes apply to your specific AICC product after May 15, 2026. Do not assume last year's codes still apply. |
| 4 | Check prior authorization requirements for every plan in your payer mix. Fee-for-service Medicare, Medicare Advantage, and Medicaid managed care plans each handle AICC prior authorization differently. The CMS policy modification may trigger updates in Medicare Advantage plan contracts. Call your top five payers and ask directly whether prior auth requirements for AICC have changed. |
| 5 | Update your medical necessity documentation templates. Your templates need to capture inhibitor titer results, documentation of standard factor therapy failure, hematologist orders, and the specific clinical indication (acute bleed, surgical prophylaxis, or routine prophylaxis). If any of those fields are missing from your current intake forms, add them now. |
| 6 | Train your clinical documentation team. The gap between what clinicians document and what billing requires is where AICC claims die. Schedule a 30-minute training before May 15, 2026 to walk through what the updated policy requires and what a complete claim looks like. Your hematology nurses and infusion center staff should understand what triggers a denial. |
| 7 | Set a post-effective-date audit. Schedule a claims review for 30 days after May 15, 2026. Pull every AICC claim submitted under the new policy and check denial rates. If you're seeing higher denials than usual, identify the pattern and fix it before it compounds. |
If your practice has significant volume in AICC billing and you're not certain whether your current workflows meet the updated standard, talk to your compliance officer and your billing consultant before May 15, 2026. The financial exposure here is too high to find out through denials.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Anti-Inhibitor Coagulant Complex Under This Policy
The policy data provided for this modification does not list specific CPT, HCPCS, or ICD-10 codes. Do not use codes from third-party sources without verifying them against the updated CMS policy and your MAC's current fee schedule.
How to Find the Right Codes
AICC products are typically billed under HCPCS J-codes assigned to specific blood clotting factor products. The exact code depends on which AICC product you're dispensing and whether billing occurs under Part B (clinical administration) or Part D (home dispensing).
Contact your Medicare Administrative Contractor directly and ask which HCPCS codes apply to your AICC product as of May 15, 2026. Also confirm the applicable ICD-10-CM diagnosis codes for inhibitor-complicating hemophilia A and hemophilia B — these diagnosis codes must align with your medical necessity documentation or your claim will reject.
Once you have confirmed codes from your MAC, map them into your charge capture system before the effective date. This is not a step to defer.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.